Seminar

Seminar

Date:
17 October 2011 00:00 hrs.
Location:
Title:
In situ Tumor Ablation by Electric Currents or Alpha Radiation and Anti-tumor Immune Responses
Speaker(s):

Prof. Yona Keisari, Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel-Aviv University, Israel

Host(s):

Prof. Gosse Adema, department of Tumor Immunology

17-10-2011 00:00:00Europe/AmsterdamIn situ Tumor Ablation by Electric Currents or Alpha Radiation and Anti-tumor Immune Responses Rimlsrimls@radboudumc.nl

Remarks / more information:

Yona Keisari

Our immunotherapeutic approach is aimed to make the tumor its own antigenic vaccine following tumor ablationin situ.This may cause spillage of antigenic molecules and consequently activation of antitumor immunological reactions, which can destroy residual cells in the primary tumor and in distant metastases.

In order to achieve efficient primary tumor ablation we developed two novel and powerful traetment modalities for solid cancer, which can be used instead or in combination with surgery.

a. The first treatment is base on the use of unipolar pulsed electric currents for the ablation of solid primary tumors (PECTA). The treatment is delivered through intratumoral electrodes, which produce toxic pH areas around the electrodes. PECTA can be enforced by the concomitant use of chemotherapeutic agents in the treatment of tumors.

b. The second cancer treatment is based on insertion of radioactive wires loaded with Ra-224. These wires release into the tumor atoms which emit highly cytotoxic alpha particles (DiffusingAlpha-emitters Radiation Treatment- DaRT). This treatment can also be augmented by chemotherapy.

We proved that these treatment modalities effectively destroy primary solid tumors, and reduce the metastatic load in experimental animal and human cancer models of melanoma, breast, colon, prostate, pancreas, lung, and squamous cell carcinomas.

Furthermore,in situablation of primary antigenic tumors led to the activation of immunological reactions, destroying remaining malignant cells in the primary tumor as well as in distant metastases. It is postulated that the immunological response can be further amplified by the use of immune response modifiers.

PECTA or DaRT together with chemotherapy and immuno-stimulatory agents, can serve as treatment protocols given instead or in combination with surgery.



<< back to all events